NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...